Marizyme Valuation
| MRZM Stock | USD 0 0 66.67% |
Marizyme seems to be undervalued based on Macroaxis valuation methodology. Our model forecasts the value of Marizyme from analyzing the firm fundamentals such as Shares Outstanding of 10.13 M, return on equity of -0.5, and Operating Margin of (180.85) % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Marizyme's price fluctuation is out of control at this time. Calculation of the real value of Marizyme is based on 3 months time horizon. Increasing Marizyme's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Marizyme pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Marizyme. Since Marizyme is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Marizyme Pink Sheet. However, Marizyme's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.003 | Real 0.008699 | Hype 0.002795 |
The intrinsic value of Marizyme's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Marizyme's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Marizyme helps investors to forecast how Marizyme pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Marizyme more accurately as focusing exclusively on Marizyme's fundamentals will not take into account other important factors: Marizyme Total Value Analysis
Marizyme is now forecasted to have valuation of 17.35 M with market capitalization of 5.07 M, debt of 495.32 K, and cash on hands of 2.04 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Marizyme fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17.35 M | 5.07 M | 495.32 K | 2.04 M |
Marizyme Investor Information
The company has price-to-book ratio of 0.37. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Marizyme recorded a loss per share of 0.39. The entity last dividend was issued on the 27th of July 2018. The firm had 1:29 split on the 27th of July 2018. Based on the measurements of operating efficiency obtained from Marizyme's historical financial statements, Marizyme is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Marizyme Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Marizyme has an asset utilization ratio of 0.32 percent. This suggests that the Company is making $0.003186 for each dollar of assets. An increasing asset utilization means that Marizyme is more efficient with each dollar of assets it utilizes for everyday operations.Marizyme Ownership Allocation
Roughly 97.96 % of Marizyme outstanding shares are held by general public with 2.04 pct. owned by insiders and only 0.0 % by institutional investors.Marizyme Profitability Analysis
The company reported the previous year's revenue of 210.28 K. Net Loss for the year was (11 M) with profit before overhead, payroll, taxes, and interest of 129.93 K.About Marizyme Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Marizyme. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Marizyme based exclusively on its fundamental and basic technical indicators. By analyzing Marizyme's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Marizyme's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Marizyme. We calculate exposure to Marizyme's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Marizyme's related companies.Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida. Marizyme operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 11 people.
8 Steps to conduct Marizyme's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Marizyme's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Marizyme's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Marizyme's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Marizyme's revenue streams: Identify Marizyme's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Marizyme's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Marizyme's growth potential: Evaluate Marizyme's management, business model, and growth potential.
- Determine Marizyme's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Marizyme's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Marizyme Growth Indicators
Investing in growth stocks can be very risky. If the company such as Marizyme does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 40.5 M | |
| Retained Earnings | -47.8 M |
Other Information on Investing in Marizyme Pink Sheet
Marizyme financial ratios help investors to determine whether Marizyme Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.